drugset
drugset / Trial / NCT04722666

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

NCT04722666 ↗

Phase 2 Terminated 199 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent

Timeline

Start
2021-07-20
Primary completion
2023-09-26
Completion
2023-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Onfasprodil Small molecule — Intravenous

Indications

major depressive disorder